top of page

Sickle Cell Therapies: Casgevy & Lyfgenia

Writer's picture: Christine JohnstonChristine Johnston

Sickle cell disease receives two FDA approved gene therapies in December of 2023 for patients aged 12 years and older. Sickle cell disease is a genetic disorder that impacts about 100,000 patients in the US and is attributed with premature death. Although commonly thought of in the African American population, it can occur across ethnicities impacting men and women the equally.  Both therapies, Casgevy & Lyfgenia, are anticipated to cost upwards of $2 million. Despite being touted as “one-time” treatments, patients and caregivers will require immense support to endure the intensive processes (requiring months to complete) the associated intensive chemotherapy and prolonged hospitalization. Lyfgenia carries a black box risk of cancer. Clinical trials are on-going. Please consult your pharmacy expertise for specific case review or questions.


Recent Posts

See All

Opioid Reversal Treatment: Opvee

Opioid reversal has another option in its toolkit. In May of 2023 the FDA endorsed Opvee, a nasal spray to reverse an opioid overdose....

Opmerkingen


Color Palette and Refreshed Logo_ Foundational Pharmacy Strategies (2).png

We partner with benefit advisors and remove the barriers to effectively navigate the pharmacy benefit for the betterment of employers and patients.

Get Started

Unlock a future where quality healthcare isn't just a dream—it's a reality for every employee, every client, and every business.

bottom of page